Skip to main content
PLOS One logoLink to PLOS One
. 2024 Jul 5;19(7):e0304451. doi: 10.1371/journal.pone.0304451

Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins

Pedro Garrido-Rodríguez 1,#, Miguel Carmena-Bargueño 2,#, María Eugenia de la Morena-Barrio 1, Carlos Bravo-Pérez 1, Belén de la Morena-Barrio 1, Rosa Cifuentes-Riquelme 1, María Luisa Lozano 1, Horacio Pérez-Sánchez 2,*, Javier Corral 1,*
Editor: Soumendranath Bhakat3
PMCID: PMC11226102  PMID: 38968282

Abstract

Serine protease inhibitors (serpins) include thousands of structurally conserved proteins playing key roles in many organisms. Mutations affecting serpins may disturb their conformation, leading to inactive forms. Unfortunately, conformational consequences of serpin mutations are difficult to predict. In this study, we integrate experimental data of patients with mutations affecting one serpin with the predictions obtained by AlphaFold and molecular dynamics. Five SERPINC1 mutations causing antithrombin deficiency, the strongest congenital thrombophilia were selected from a cohort of 350 unrelated patients based on functional, biochemical, and crystallographic evidence supporting a folding defect. AlphaFold gave an accurate prediction for the wild-type structure. However, it also produced native structures for all variants, regardless of complexity or conformational consequences in vivo. Similarly, molecular dynamics of up to 1000 ns at temperatures causing conformational transitions did not show significant changes in the native structure of wild-type and variants. In conclusion, AlphaFold and molecular dynamics force predictions into the native conformation at conditions with experimental evidence supporting a conformational change to other structures. It is necessary to improve predictive strategies for serpins that consider the conformational sensitivity of these molecules.

Introduction

Serpins are a superfamily of proteins sharing a common, strongly conserved structural configuration required to inhibit serin proteases. Even serpins with no inhibitory activity share a single common core domain consisting of 3 β strands, 7–9 α helices, and a reactive center loop (RCL) for the interaction with target proteases [1]. Serpins are folded into a native conformation with 5 β strands in the central A sheet and a RCL, which means a metastable stressed structure with inhibitory activity (Fig 1A). This configuration allows serpins to change their structure to a relaxed hyperstable form with 6 β strands in response to stimulus, usually by the cleavage of the RCL by their target protease (Fig 1C) [2]. This efficient suicidal mechanism explains the key role of serpins in several crucial systems based on proteolytic cascades in a wide range of species. It is the case of coagulation, inflammation or the complement system. Such structural sensitivity also makes serpins particularly vulnerable to even minor modifications caused by environmental conditions or missense mutations, which may cause a conformational instability with pathogenic consequences [3], as other hyperstable relaxed conformations with no inhibitory activity may be generated, such as latent structure (when the RCL is inserted into the own molecule) or polymers (if the insertion involves another molecule), both without inhibitory activity (Fig 1D). Moreover, polymers may be toxic if accumulated in the cell [4]. These aberrant conformations, caused by a wide range of mutations affecting SERPINA1, SERPINC1, SERPINI1 or SERPING1, are responsible for disorders of relevance, such as emphysema, thrombosis, neuropathies or angioedema, respectively [5]. Moreover, environmental conditions may also induce conformational changes in serpins [6].

Fig 1. Serpins conformations.

Fig 1

(A) Native or stressed conformation (PDB: 1AZX-I). (B) Cleaved state (PDB: 1EZX). (C) Latent or relaxed conformation (PDB: 1AZX-L). (D) Dimer structure, exchanging two central β-strands (PDB: 2ZNH). White, red and dark blue: serpin (antithrombin or α-1-antitrypsin). Cyan: central wild-type β-strands. Magenta: reactive center loop. Light blue: trypsin.

One of the best-known serpins is antithrombin, probably the most important endogenous anticoagulant [7]. Its deficiency dramatically increases the risk of thrombosis, even when it impacts a single allele, acting as a dominant disorder. Antithrombin deficiency can be classified into two groups. Type I when the mutation, by different mechanisms, severely affects the levels of variant antithrombin in plasma. Type II, if the mutation does not severely impair the secretion of the antithrombin variant which has impaired or null anticoagulant activity. More than 386 different variants affecting SERPINC1, the gene encoding antithrombin, have been described as causative of antithrombin deficiency [8].

One great challenge for antithrombin and all other serpins is how to predict the consequences of any new mutation, as they may have a wide range of consequences with clinical impact. Thus, certain mutations may cause intracellular polymerization that cause severe type I deficiency with serious clinical impact, others favor the transition to latent conformation with no functional activity, being responsible for type II PE deficiency also with severe clinical phenotype, and other mutations only disturb functional domains of the serpin (heparin binding domain or the RCL), leading to type II deficiency with usually milder clinical impact [8], being particularly interesting to identify those with a conformational effect [9].

Overall, the prediction of 3D protein structures based on their sequences is a long-lasting problem in biochemistry [10]. Likewise, it has also been a noteworthy challenge for artificial intelligence (AI) systems since the advent of bioinformatics, and we can see nowadays that AI methods have started to slightly increase the accuracy of structural predictions [11]. In 2021, Jumper et al. [12] released AlphaFold, their AI model for protein structure prediction. The model developed by DeepMind has created high expectations in the community [13] because of its outstanding results on the 13th edition of Critical Assessment of Structure Prediction (CASP) [14] using the first version of the model [15], and more recently in CASP 14 [16] with the new AlphaFold 2 [12]. The model, now released to the community, is expected to ease the efforts needed to solve the 3D structures of several proteins yet unknown [17]. Nonetheless, the structural resolution of non-novel, mutated proteins could mean a huge step forward in several areas. Although its authors state it is not validated to predict mutational effects [18] and flipping an amino acid in the target protein to model a mutation will not work in AlphaFold [19, 20], it would be interesting to challenge the model to solve the conformational consequences of mutations affecting serpins, as these mutations cause a relevant structural change compared with the native conformation.

Molecular Dynamics (MD) simulation is an established and routinary methodology for the prediction of the dynamical evolution of biomolecular structure with atomic detail [21]. Indeed, the first MD simulation of a simple protein system was carried out in 1977 [22], while recently MD allowed the simulation of the SARS-CoV-2 spike protein, implying millions of atoms [23]. Nonetheless, it should be mentioned that the main limitations of the MD technique are related, among others, to the required computing time, which depends mainly on the system size and the trajectory length needed. Advances in hardware in the last decade allow nowadays to perform millisecond simulations for proteins of average size such as p53 [24]. While parallelization techniques have significantly advanced the field of MD simulations, allowing for more complex and longer simulations, there remain inherent challenger in modelling time-dependent processes even with parallelization [25].

Thus, in this study we have explored the accuracy of AlphaFold and molecular dynamics predictions for different environmental conditions inducing conformational changes in antithrombin, as well as for natural mutants of antithrombin identified in our cohort of patients. All selected cases have variant antithrombins detected in plasma, ensuring both folding and secretion of variants, and were deeply studied using different biochemical methods providing information on their conformation, including a case whose crystal structure was determined.

Materials and methods

Patients

For 23 years (1998–2021) our group has recruited one of the largest cohorts of unrelated patients with antithrombin deficiency (N = 350). After molecular analysis of SERPINC1, the gene encoding this key anticoagulant, using sequencing methods and Multiple Ligand Probe Amplification (MLPA) methods to identify small and gross genetic variants, 135 different SERPINC1 gene defects were found in 250 patients. Experimental characterization of plasma antithrombin in these cases, described extensively elsewhere [2628] included functional analysis of anti-FXa and anti-FIIa activities by using chromogenic methods. These functional assays evaluated the inhibitory activity of plasma antithrombin. Moreover, in all these samples we also quantified antithrombin antigen levels by immunological methods, identified forms with low heparin affinity by crossed immunoelectrophoresis in the presence of heparin, and evaluated plasma antithrombins by native (in the presence and absence of 6M urea) and denaturing PAGE and western blotting, procedures that allow detection of aberrant forms of antithrombin and a semi-quantitative determination of the latent conformation [29].

For this study, we selected 5 different variants (Table 1). The rational of this selection was: 1) the variant generated antithrombin variants detected in the plasma of carriers; and 2) availability of biochemical experimental data, which may include the recombinant expression in eukaryotic cells of the mutated variant [30], its purification from plasma and in one case a crystallographic characterization. Moreover, this selection also aimed to cover the range of different mutations, from simple missense to the insertion of a different number of residues in the structure of antithrombin (Fig 2).

Table 1. Functional antigenic and biochemical data of SERPINC1 mutations identified in patients with antithrombin deficiency and selected for predictions using AlphaFold.

Mutation ID N Anti-FXa (%) Antigen (%) Low Hep Aff CIE Latent Native Urea Dimers Ref Other data
p.Arg79Cys M1 19 42.6 ± 9.8 91.6 ± 11.1 Yes -- -- [31] --
p.Pro112Ser M2 1 50 55 -- -- Yes [32] --
p.Met283Val M3 1 76 98 Yes Yes -- [26] --
p.Pro352insValPheLeuPro M4 5 47.5 ± 8.9 58.0 ± 1.7 -- -- Yes [33] Verified by proteomic
p.Glu241_Leu242delinsValLeuValLeuValAsnThrArgThrSer M5 1 57 80 Yes Yes -- [34] Crystal structure

ID: variant alias; N: number of carriers; Anti-FXa: anti Factor Xa activity (% compared to normal levels); Antigen (% compared to normal levels); Low Hep Aff: low heparin affinity forms observed by crossed immunoelectrophoresis; Ref: article describing the variant.

Fig 2. Selection of variants for this study.

Fig 2

Variants were selected from a cohort of 350 patients with antithrombin deficiency and were previously described in different works.

Structure processing

The sequences in FASTA of all proteins (wild-type and M1-M5) were used to obtain AlphaFold predictions. The 3D crystal structures were obtained from the Protein Data Bank (PDB) with codes 1AZX (wild-type) and 4EB1 (M5). These structures were preprocessed with Maestro Tool Protein Preparation Wizard [35] to fix potential problems with hydrogens that could crash between them. Proteins were processed to add charges using Maestro System Builder tool with OPLS3e force field.

AlphaFold predictions

Monomer predictions were obtained running AlphaFold v2.0.1 [12, 36], on its simplified version, i.e., with no templates and a reduced Big Fantastic Database (BFD). Dimerization simulations were obtained with AlphaFold Multimer model [37]. UCSF ChimeraX v1.3 [38] was used to obtain metrics for AlphaFold results. Pruned RMSD refers to RMSD computed excluding from the process unstructured or flexible structures to avoid potential biases on the RMSD computation. These results were represented using PyMol v2.5. Hydrogen bond analysis was performed with ChimeraX as described elsewhere [38, 39].

We decided to run the aforementioned configuration for AlphaFold as (i) it requires less computational resources; (ii) AlphaFold authors claim accuracies to be nearly identical to the regular v2.0.1 for most of the proteins [36], we see no differences between both configurations, i.e. reduced and full AlphaFold (Table 2 and Fig 3); and (iii) antithrombin belongs to the serpin protein superfamily. That means it is not part of the reduced group of proteins showing significant differences between the complete and simplified model, as serpin proteins all have a very similar, conserved structure and are well represented in the databases used to build BFD. Aiming to evaluate the effect of each mutation, we run a script of Rosetta Online Server that Includes Everyone (ROSIE 2) [40] to stabilize proteins with a point mutation (https://r2.graylab.jhu.edu/apps/submit/stabilize-pm) and we compared the results obtained by both methods. The difference of free energy (ΔΔG) of each protein was calculated in Rosetta Energy Unit (REU). A value of ΔΔG higher than 0 indicates that’s exists a destabilizing mutation.

Table 2. Summary of AlphaFold metrics between predictions of reduced and full (reference) versions.

We observe no differences between full and reduced AlphaFold models.

Protein RMSD mean (Å) RMSD maximum (Å) lDDT
Wild-type 0.015 0.030 0.995
M5 0.014 0.030 0.999

Fig 3. Results for reduced (green) and full (blue) versions of AlphaFold.

Fig 3

(A) Wild-type antithrombin predictions. (B) M5 predictions. No major differences are perceived for antithrombin between reduced and full AlphaFold versions.

Molecular dynamics

All considered protein structures were subjected to MD simulations with MD engine Desmond [41] included in the Maestro Suite [42]. First, all protein models were immersed in a box, whose dimensions were 10x10x10 Å, with water molecules with the simple point charge (SPC) water model. Ions of Sodium and Chlorine were added to neutralize charges and to obtain a molarity of 0.15 M. This step made use of Maestro System Builder tool. Complexes were passed to MD with the following parameters: energy minimization was made by 2000 steps using the steepest descent method with a threshold of 1.0 kcal/mol/Å. The NPT simulations were realized at the exact temperature in each case: 300, 313 and 373 K with the Nosé-Hoover algorithm [43, 44] and the pressure was maintained at 1 bar with the Martyna-Tobias-Klein barostat [44, 45]. The length of performed MD simulations was 100ns or 1000ns. Periodic conditions were used. The cutoff of 9 Å was established to van der Waals interactions and the Particle Mesh Ewald (PME) method with a tolerance of 10–9 was used in the electrostatic part. The force field used in all runs was OPLS3e [46].

Metrics

In order to evaluate the accuracy of the structural predictions obtained by AlphaFold and MD simulations, the Secondary Structure Elements (SSE), the Root Mean Squared Deviation (RMSD), the Root Mean Squared Fluctuation (RMSF) and the Local Distance Difference Test (lDDT) [47] metrics were considered for each protein model, when comparing against available crystal structure. To evaluate the changes produced in the secondary structure of proteins along the trajectory, Maestro Simulation Interaction Diagram (SID) tool was used under version 2020–04, in order to show the evolution of α-helices and β-strands along the whole simulation. This tool analyzes many properties of the protein, such as RMSD, RMSF and SSE. SID shows a summary of SSE in all residues of the protein, so this analysis can be used to evaluate if a residue (or a group of residues) changes its secondary structure along the simulation. RMSD evolution for each protein was computed using SID. RMSD is a measurement of the global stability of the protein along the simulation. RMSF evolution for each protein was also computed using SID. RMSF measures the stability of each residue along the whole simulation. To compute both RMSD and RMSF, SID takes the first frame as reference and superimposes all the frames against the aforementioned to evaluate protein fluctuations along the trajectory. In each case, values over 3 Å mean that the protein (RMSD) of a specific region (RMSF) is not stable. lDDT was performed using lDDT Swiss-Model Tool (https://swissmodel.expasy.org/lddt/downloads). This score is a measurement of the difference between the local interactions of two proteins. This tool was used in the CASP9 (Critical Assessment of protein Structure Prediction 9: https://predictioncenter.org/casp9/index.gci).

In addition, Free Energy Landscape (FEL) analysis combined with PCA and the covariance matrix generation were calculated using GROMACS 2022.2 [48] modules named covar and anaeig when processing Desmond MD trajectories via Maestro Tool: trj convert [11]. Subsequently, 3D FEL figures were obtained using the Python library matplotlib 3.5.2 [49]. Pathogenicity predictions were gathered for each variant when available using Varsome v11.3 [50]. Additionally, Ramachandran plots were generated for each structure analyzed as a quality control step (S1 Fig). The dihedral angles and G-factor were calculated using BioLuminate software included in Maestro Suite [51].

Ethical considerations

All methods and experimental protocols used in this study have been carried out following current guidelines and regulations. This study was approved by the local Ethics Committee of Morales Meseguer University Hospital and performed in accordance with the 1964 Declaration of Helsinki and its later amendments. All included subjects and/or their legal guardian(s) gave their written informed consent to enter the study. Patients’ data were gathered between 24/01/2022 and 27/01/2022. Researchers did not have access to information that could identify individual participants during or after data collection.

Results

Mutations evaluated

Table 1 shows the mutations selected, the consequences on the protein and the experimental data obtained in each variant.

We selected three missense mutations:

  1. p.Arg79Cys (M1). This mutation causes a type II HBS deficiency (Antithrombin Toyama variant) [31], as it changes one arginine residue directly involved in the interaction with heparin [52], the cofactor of antithrombin that fully activates this serpin increasing up to 1000-fold its anticoagulant activity [53]. Moreover, this is one of the most recurrent variants identified in our cohort (N = 19 unrelated cases). All carriers of this variant have reduced heparin cofactor activity, normal antigen levels and the mutated antithrombin (which constitutes half of the plasma antithrombin) has faster electrophoretic mobility in native-PAGE and low heparin binding under crossed immunoelectrophoresis with heparin. Finally, this residue has also been mutated to Ser or His in other patients with type II HBS deficiency.

  2. p.Pro112Ser (M2). This mutation causes a severe reduction of antithrombin levels in plasma, probably by inducing intracellular polymerization according to the detection of disulfide-linked dimers in plasma, as our group previously demonstrated [32].

  3. P.Met283Val (M3). The patients carrying this mutation had high antigen levels, with the increase of a form with low heparin affinity, and increased levels of latent antithrombin as demonstrated by our group, all data supporting a type II PE deficiency [26].

We also included in our study two mutations with greater consequences in the amino acid sequence of antithrombin:

  1. C.1154-14G>A, which created a new splicing acceptor site in intron 5. The resulting mRNA maintained the reading frame of antithrombin with the insertion of 4 new residues p.Pro352insValPheLeuPro (M4) [33]. This new variant might induce polymerization of the variant antithrombin, as a severe reduction of antigen levels was observed in 5 unrelated carriers of this recurrent mutation. We also detected the presence of disulfide-linked dimers in plasma, which were slightly bigger than those identified in carriers of the p.Pro112Ser mutation. The purification and proteomic analysis of disulfide-linked dimers from carriers’ plasma confirmed the insertion of the predicted 4 additional amino acids in the variant antithrombin [54].

  2. c.722_725delins[731_751;GAACCAG], which caused a complex insertion p.Glu241_Leu242delinsValLeuValLeuValAsnThrArgThrSer (M5) in a very conserved region of serpins. The carrier of this mutation had a type II deficiency with increased levels of a form with low heparin affinity and hyperstable antithrombin. Moreover, structural analysis with the recombinant protein revealed a relaxed structure with the inserted residues forming a new strand in the central A sheet and a native RCL [34].

S1 Table shows pathogenicity prediction for selected mutations.

AlphaFold predictions

Firstly, we compared the structure of native antithrombin (PDB:1AZX) with the one predicted by AlphaFold for the wild-type sequence of human antithrombin (https://www.uniprot.org/uniparc/UPI000002C0C1). As shown in Fig 4A, AlphaFold predictions were quite accurate, despite some differences concerning the starting or end of helix or strands. Differences are summarized as RMSD in Table 3.

Fig 4. Comparisons between wild-type antithrombin prediction and different structures.

Fig 4

(A) 1AZX. (B) M1. (C) M2. (D) M3. (E) M4. (F) M5. White: 1AZX. Blue: AlphaFold prediction for wild-type antithrombin. Green: corresponding mutation. Red: mutated residues. Strong correlation between wild-type, native structure and mutant predictions is observed, even for bigger changes, such as M4 and M5. M4 is included as a loop in the main structure, whilst M5 is modeled as an α-helix, as this configuration has higher thermodynamical stability than a 10-residue loop.

Table 3. Summary of metrics for AlphaFold and molecular dynamics.

AlphaFold metrics are referred to its predictions, except for PDB:1AZX and PDB:4EB1. Molecular Dynamics metrics refer to differences between initial and final state of the proteins.

AlphaFold
Structure A Structure B RMSD (Å) pruned RMSD (Å) all pairs
Wild-type PDB:1AZX 0.858 2.431
M1 0.302 2.628
M2 0.320 2.999
M3 0.377 2.812
M4 0.504 7.355
M5 0.347 1.675
PDB:4EB1 0.940 4.003
Wild-type 0.933 3.890
Molecular Dynamics
Simulation time (ns) Protein RMSD (Å) lDDT RMSF man (Å) RMSF maximum (Å)
1000 Wild-type 1.785 0.716 1.005 6.013
M3 1.685 0.733 1.008 6.546
100 M1 1.422 0.725 1.005 3.860
M2 1.748 0.729 1.104 5.564
M4 1.481 0.733 1.012 4.035
M5 1.668 0.710 1.022 5.091

Then, we compared AlphaFold prediction for the wild-type antithrombin with the predictions of the same software for all selected mutants. As expected, the functional variant M1 only caused a minor modification of the structure, even at the mutated residue (Fig 4B and Table 3).

The comparison of the other two missense mutations included in this study was quite similar, with minor mismatches (Fig 4C, 4D and Table 3). These three mutations (M1, M2 and M3) were analyzed using Rosetta Online Server that Includes Everyone (ROSIE 2). The results showed that all mutations have a value of REU higher than the native (Table 4), thus all were destabilizing, especially M2, with an energy difference of 5.88 REU. M1 and M3 have an energy difference close to 2 REU. Furthermore, we compared ROSIE 2 predictions with AlphaFold’s. These comparisons are summarized in Table 4.

Table 4. Summary of RMSD metrics of the difference of energy in REU (Rosetta energy units) between the wild-type and each mutant.

Differences between ROSIE 2’s predictions and AlphaFold’s are presented as RMSD and lDDT.

Protein Energy (REU) RMSD (Å) lDDT
M1 2.27 0.987 0.8371
M2 5.88 0.974 0.8496
M3 1.9 1.133 0.8272

Interestingly, AlphaFold also produced a native structure for variants causing insertions of residues. For the small insertion of 4 amino acids caused by the intronic mutation (M4), AlphaFold predicted a small elongation of the loop connecting hI and s5A (Fig 4E and Table 3).

For the M5 variant, the inserted new residues are forced into a new small helix but maintained the native structure (Fig 4D), which differed significantly from the crystal structure of this variant (4EB1) (Fig 5 and Table 3). The analysis of dihedral angles revealed that residues Ala206, Ile207 and Asn208 adopted different secondary structures in the M5 crystal compated to the AlphaFold prediction. In M5 crustal these residues are part of a β-strand, whereas in the AlphaFold they form a right-handed α-helix (Tables 5 and 6). The information of the Chi1, Chi2 and G-factor are summarized in S2 and S3 Tables.

Fig 5. Cross-section of M5 crystal (4EB1) compared to its AlphaFold prediction.

Fig 5

White: M5 crystal (4EB1). Green: M5 prediction. Cyan: natural serpins β-strands. Orange: 10 amino acid insertion on crystal. Red: 10 amino acid insertion on M5 prediction. 4EB1 shows how M5 insertion leads to an extra β-strand in patients, resembling a latent structure, whilst AlphaFold predicts M5 insertion to be fold as a new α-helix, with no change of the native, wild-type-like structure.

Table 5. Dihedral angles (Phi/Psi) summary for the wild-type and M5 mutant.

A comparison of crystal structures and AlphaFold predictions.

Residue 1AZX 4EB1 M5 AlphaFold
Φ Ψ G-Factor Φ Ψ G-Factor Φ Ψ G-Factor
Ser204 -61.12 142.8 -4.287 151.14 125.93 -5.91 -55.45 147.54 -4.503
Glu205 73.51 -10.43 -10.52 158.48 169.79 -6.697 64.66 -9.44 disallowed
Ala206 -61.86 -30.56 -2.958 150.61 133.67 -6.326 -59.39 -45.66 -2.772
Ile207 116.23 139.86 -4.15 122.41 131.25 -3.27 -69.84 -37.99 -2.785
Asn208 144.57 179.74 -6.518 120.64 127.64 -5.57 -60.8 -43.38 -2.583
Thr211 79.4 140.8 -5.42 -63.58 124.65 -6.222 129.23 86.68 -7.127
Val212 129.16 -33.09 -8.445 103.82 -44.39 -6.36 -91.82 118.55 -4.407
Leu213 -154.8 134.71 -6.027 150.11 143–98 -6.076 119.73 120.64 -4.606
Val214 135.19 137.84 -4.226 125.08 118.29 -3.956 112.88 121.97 -3.67
Leu215 105.47 132.19 -4.114 -92.02 124.16 -4.712 -92.25 126.78 -4.665

Table 6. Secondary structure comparison for the wild-type and M5 mutant.

Analysis of crystal structures and AlphaFold predictions.

Residue 1AZX 4EB1 M5 AlphaFold
Ser204 β-strand β-strand β-strand
Glu205 Turn/loop β-strand Turn/loop
Ala206 right-handed α-helix β-strand right-handed α-helix
Ile207 β-strand β-strand right-handed α-helix
Asn208 Turn/loop β-strand right-handed α-helix
Thr211 β-strand β-strand β-strand
Val212 right-handed α-helix right-handed α-helix β-strand
Leu213 β-strand β-strand β-strand
Val214 β-strand β-strand β-strand

When analyzing changes in the hydrogen bond network (HBN) of the different structures, we observed little differences between the hydrogen network of AlphaFold’s wild-type and its predictions for point mutations (Table 7), sharing nearly 90% of intra-chain connections via hydrogen bonds. Nonetheless, when comparing 1AZX HBN with 4EB1 and M5, we find the latter having more in common with the native crystal than 4EB1. The differences between the HBN of M1-M3 and M4-M5 arise from the insertion of new residues, creating and destroying hydrogen bonds, thus changing the HBN.

Table 7. Analysis of the hydrogen bond network, a comparative summary.

Comparison of pairs of residues linked by at least one hydrogen bond in each structure. Structure A is the reference on each analysis. Structure B is the corresponding AlphaFold prediction.

Structure A Structure B % shared HBN
1AZX-I Wild-type 60.00%
M5 19.00%
4EB1-I 15.00%
Wild-type M1 89.00%
M2 88.00%
M3 89.00%
M4 47.00%
M5 26.00%
4EB1-I M5 54.00%

Also, we evaluated the differences between the reduced and complete version of AlphaFold with both wild-type protein and M5. We selected the wild-type sequence for benchmarking as AlphaFold has been validated with wild-type proteins, and M5 as it is the most aberrant and challenging variant for modeling on our study. Resulting metrics (Table 2) showed virtually nonexistent differences between both versions of AlphaFold, validating thus the applicability of the reduced version of AlphaFold, as its results are comparable to those obtained with the complete version of the model.

Additionally, we wanted to address if AlphaFold Multimer model [37] was capable of predict a correct dimerization for mutations known to produce such outcome (M2, M4). Multimer results are presented on S2 Fig. We observe AlphaFold Multimer predicts dimers for both mutations, providing the same consequence as the predicted for the wild-type protein (i.e., exchange of a single β-strand with its counterpart).

Molecular dynamics

The overall structure of wild-type antithrombin did not change significantly with simulations at 1000 ns and low (27°C), high (40°C) or extreme temperatures (100°C), with the RCL released, showing a stressed structure. Indeed, the structure was also similar (stressed native) for variants secreted with a relaxed structure (M3 and M5) with minor changes near the mutations [42]. Metrics are summarized in Tables 3, 4, 8 and 9. PDF reports with all the metrics (RSMD, RSMF and SSE) are included in the supplementary file (S1 File).

Table 8. Summary of RMSD metrics between initial and most energetically stable MD states for all studied proteins.

Local minimums were calculated using FEL calculations.

Protein Local minima (n) RMSD (Å) local minimum 1 RMSD (Å) local minimum 2 RMSD (Å) local minimum 3
Wild-type 2 1.877 1.646 -
M1 3 1.596 1.615 1.541
M2 3 1.820 1.832 1.718
M3 2 1.754 1.735 -
M4 2 1.703 1.614 -
M5 1 1.732 - -

Table 9. Summary of lDDT metrics between initial and state with less energy for all considered proteins.

Protein Local minima (n) lDDT local minimum 1 lDDT local minimum 2 lDDT local minimum 3
Wild-type 2 0.723 0.736 -
M1 3 0.724 0.731 0.727
M2 3 0.723 0.721 0.727
M3 2 0.717 0.734 -
M4 2 0.723 0.746 -
M5 1 0.717 - -

We also studied the different proteins using the FEL approach [55] to find the most energetically stable pose within the trajectory and compared its conformation against the initial MD trajectory. These conformations are local minimums. A summary of obtained results is shown in Tables 6 and 7. Details regarding 3D FEL figures are presented in S3 Fig.

Discussion

The structural flexibility of serpins, required for their efficient inhibitory mechanism, also makes these molecules particularly sensitive to environmental conditions (pH, temperature, redox conditions) with both physiological and pathological consequences [5661]. Even minor missense mutations might disturb the stressed native conformation and ease the transition to relaxed hyperstable non-inhibitory conformations with the RCL inserted (mainly latent or polymers) [3]. However, there are other mutations affecting RNA stability or translation leading to quantitative deficiency of serpins and could have pathological consequences. Finally, there are also mutations affecting functional domains that, with minor effects in folding or secretion, cause a qualitative deficiency with inactive variants also involved in different disorders [8]. Hemostatic serpins, particularly antithrombin, are excellent examples of the pathogenic impact of these environmental conditions and types of mutations [3, 9, 62]. Thus, it would be of great interest to have tools able to predict the effect of mutations affecting serpins, particularly those causing transitions to the latent or polymer conformations as they seem to have higher clinical severity [63], probably by a dominant negative effect additional to the loss of function associated to these mutations [64, 65], and by potential additional deleterious consequences if accumulated intracellularly.

In this study, we explored the predictions of AlphaFold, a novel artificial intelligence system conceived to predict structures of new proteins, and molecular dynamics, a computer simulation method for analyzing the physical movements of atoms and molecules on the consequences of five SERPINC1 mutations causing antithrombin variants, four of them with experimental evidence supporting a conformational change, as well as the effect of high temperatures that caused conformational changes even in wild-type antithrombin [56].

AlphaFold gave an accurate prediction of the wild-type antithrombin structure. Similarly, M1, a recurrent functional mutation that impairs the binding of antithrombin to its cofactor heparin, caused a minor defect in the structure predicted by AlphaFold. However, AlphaFold also maintained the native conformation for all other mutations with experimental evidence supporting a strong conformational consequence, both polymer/dimer formation (M2, and M4), latent transition (M3) or a new relaxed structure formed as a consequence of a relatively large insertion (M5). It has been argued that AlphaFold has not been designed to predict the effect of SNVs [20], but as shown for the cases with 4 to 10 residues insertion, using either reduced or full versions, it only adapts the inserted residues to the structure with minor deviations of the native conformation. Thus, for the in-frame insertion of 4 residues (M4), AlphaFold expands a loop to include the new 4 residues, and for the more complex variant M5, a small helix containing the 10 inserted residues was generated.

To check the dimer results for M2 and M4, we ran AlphaFold Multimer [37] (S2 Fig). We found both M2 and M4 do form dimers. Nonetheless, we also find AlphaFold Multimer output dimers for wild-type. Indeed, the dimer structure AlphaFold computes form M2 and M4 is the same as the computed for the wild-type sequence, exchanging one β-strand with the A sheet of the other molecule. Moreover, the dimer computed does not correspond to the experimentally determined models (such as PDB: 2ZNH, Fig 1D), in which two β-strands are exchanged between the two counterparts. We include images presenting each scenario below for further clarification on our results regarding AlphaFold Multimer, highlighting in purple the β-strands exchanged.

Regarding ROSIE2 results, we found higher values of REU (more destabilization) for one of the mutations whose mechanism is based on structural disruptions (M2). Still, in contrast, we got lower REU values for M3 (structural disruption) than for M1 (whose mechanism does not change the protein structure). Overall, we find ROSIE2 predictions may help to determine the pathogenicity potential of some mutations, but there seem to be better methods to evaluate missense mutations in serpins altogether.

Molecular dynamics also maintain the native conformation for all variants causing relaxed structures, even creating a new helix for the more complex variant. But the prediction also yielded the native conformation when the experiments were executed under environmental conditions that exacerbated or directly induced conformational changes (transition from native to relaxed) of mutants, and even the wild-type molecule (40°C and 100°C).

Thus, these two predictive tools forced the folding of antithrombin to the native stressed conformation even for mutations or conditions that render relaxed structures with experimental evidence.

The explanation for these incorrect predictions may be found in the PDB database. This database contains 334 entities annotated as serpins (with PFAM identifier PF00079), most of them in the native conformation. Indeed, only 36 of those remain when searching for latent. Interestingly, for human antithrombin, the first crystal structure obtained simultaneously by two independent groups contains a dimer of a latent and a native molecule [6668]. This misbalance of structures with native conformation, and the strong effect of using a specific structure for molecular dynamics studies may lead these predictive tools to force a native structure as the final result of all predictions, even over the own crystal as it occurs for the M5 complex insertion [34]. Therefore, it is necessary to improve predictive tools of folding for serpins, which must consider the conformational sensitivity of these molecules and the transition to hyperstable conformations as the most feasible folding associated with disturbing mutations. In the case of MD simulations, we hypothesize these limitations might be overcome if we could reach longer time scales where such structural rearrangements occur, using specialized and private supercomputers such as ANTON-3 [69], or applying special MD techniques that force sampling of specific events such as accelerated MD or Metadynamics [7072]. Nonetheless, MD results of all proteins showed no significant differences. If we could run multiple MD with different initial seeds, perhaps we could appreciate changes between MD simulations for each protein. Furthermore, recent implementations of novel machine learning methods coupled with molecular dynamics may improve the research on the proteins’ conformational ensemble [11]. As for AlphaFold, an in-depth study of the method and understanding of the code and training process might allow providing protein-targeted predictions for this family of serpin structures with higher accuracy [73].

In this work, we assessed whether AlphaFold could generalize outside of its established range of applicability. It is important to clearly define the capabilities and limitations of AlphaFold, given that if the model was able to generate 3D structures of mutated proteins it would be a huge step forward in several areas of Biomedical research. Rare Diseases research is an example, where given the limited number of patients and resources, it is not always feasible to crystallize mutant proteins to assess the pathogenicity of observed variants. In such cases, having access to a model capable of predicting the structural consequences of mutations would be a great improvement.

Despite other studies analyzed AlphaFold capabilities with point, simulated mutations, this study includes actual variants, found in patients. Furthermore, we include point mutations, like previous studies have done [20], as well as insertions (M4, M5) and a bigger rearrangement (M5, of which we also have access to its crystal, 4EB1 [34]) to assess AlphaFold capability to generalize out of the serpin structures the model has already seen on its training.

Moreover, AlphaFold is partially based on a neural network. Such systems are a “black box model”, making it difficult to guess how they make decisions or why they create a certain output. Thus, running it with different inputs (in this case, sequences of different nature, wild-type, point mutations, rearrangements) may give some clues on how the network is internally working. The results of variants M4 and M5 suggest that AlphaFold is creating relatively simple structures as loops or small helices to accommodate the mutated sequence outside of the main structure, so it does not obstruct in the reconstruction of the native templates seen during the model’s training.

Limitations

The scope of this work is a specific protein superfamily with a highly preserved functional structure. Thus, our conclusions may not apply to all proteins, but to those families with conserved structures across its members. Moreover, whilst efforts are being made to predict structural outcomes of missense variants, we also included in this work two INDELs (M4, M5). Current methods to model the structures of these mutations are not fully developed, nor explored, which may have limited out toolkit to work with them herein.

Conclusions

In summary, we observed that AlphaFold force predictions into the native conformation, even for mutations with experimental evidence of a conformational change. Moreover, these predictions are not capable of transitioning over time, even when simulated with molecular dynamics under extreme conditions leading to mentioned transition, such as extreme heat. Thus, we find necessary to improve predictive strategies for serpins, considering the conformational sensitivity of these molecules. In a broader sense, it is necessary to elaborate on the current structural prediction methods to allow the accurate prediction of mutant proteins overall [14, 16].

Supporting information

S1 Fig. Ramachandran plots for structures analyzed.

Mutant structures correspond to AlphaFold prediction for said variant. Plots entitled in caps and italics refer to stated PDB crystal structures.

(TIF)

pone.0304451.s001.tif (3.8MB, tif)
S2 Fig. AlphaFold Multimer predictions.

a) M2. b) M4. c) Wild-type. Green and blue: antithrombin. Purple: exchanged β-strand.

(TIF)

pone.0304451.s002.tif (3.6MB, tif)
S3 Fig. Free Energy Landscape profiles for all studied proteins after analysis of their MD trajectories.

The X and Y axes represent PC1 and PC2 PCA components and the Z axis free energy value. a) Wild-type, b) M1, c) M2, d) M3, e) M4, f) M5.

(TIF)

pone.0304451.s003.tif (1.5MB, tif)
S1 File. Reports of MD simulations.

WT, M3 and M5 were simulated at 300K, 313 K, and 373K. These reports contain information about RMSF, RMSD and SSE.

(ZIP)

pone.0304451.s004.zip (7.7MB, zip)
S1 Table. Pathogenicity predictions for selected variants.

(PDF)

pone.0304451.s005.pdf (125.2KB, pdf)
S2 Table. Comparing side-chain conformations of the wild-type and M5 mutant.

An analysis of Chi1 and Chi2 dihedral angles from crystal structures and AlphaFold Predictions.

(DOCX)

pone.0304451.s006.docx (18.4KB, docx)
S3 Table. Assessing the quality of the wild-type and M5 mutant structures.

A comparison of G-factors from crystal structures and AlphaFold predictions.

(DOCX)

pone.0304451.s007.docx (18.8KB, docx)

Acknowledgments

Pedro Garrido-Rodríguez hold a contract from CIBERER (U765—CB15/00055). Miguel Carmena-Bargueño is a predoctoral student founded by the Plan Propio de Investigación, UCAM. Authors would like to thank to the supercomputing infrastructure of the NLHPC (ECM-02), Powered@NLHPC, by the Plataforma Andaluza de Bioinformática of the University of Málaga, and the Extremadura Research Centre for Advanced Technologies (CETA−CIEMAT) for their support in this study.

Data Availability

Code used to run AlphaFold is freely available on DeepMind’s GitHub (see references). Software used for MD is property of Schrödinger LCC. Thus, access to it might be restricted. GROMACS and matplotlib codes are available at https://manual.gromacs.org/current/download.html and https://matplotlib.org/stable/users/installing/index.html, respectively. Variants p.Arg79Cys, p.Pro112Ser, p.Met283Val, p.Pro352insValPheLeuPro and p.Glu241_Leu242delinsValLeuValLeuValAsnThrArgThrSer, mentioned in our work, are deposited in UniProt as VAR_007037, VAR_086227, VAR_027468, VAR_086198 and VAR_086197, respectively.

Funding Statement

JCC received funding in the form of a grant from Instituto de Salud Carlos III (PI21/00174; PMP21/00052; JR22/00041) and from Fundación Séneca (21886/PI/22). CBP received funding in the form of a grant from Instituto de Salud Carlos III (JR22/00041). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Gettins PGW. Serpin structure, mechanism, and function. Chem Rev. 2002;102: 4751–4803. doi: 10.1021/cr010170+ [DOI] [PubMed] [Google Scholar]
  • 2.Pike RN, Bottomley SP, Irving JA, Bird PI, Whisstock JC. Serpins: Finely Balanced Conformational Traps. IUBMB Life (International Union of Biochemistry and Molecular Biology: Life). 2002;54: 1–7. doi: 10.1080/15216540213825 [DOI] [PubMed] [Google Scholar]
  • 3.Huntington JA. Serpin structure, function and dysfunction. Journal of Thrombosis and Haemostasis. 2011;9: 26–34. doi: 10.1111/j.1538-7836.2011.04360.x [DOI] [PubMed] [Google Scholar]
  • 4.Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet. 2002;3: 759–768. doi: 10.1038/nrg907 [DOI] [PubMed] [Google Scholar]
  • 5.Carrell R, Corral J. What can Drosophila tell us about serpins, thrombosis and dementia? BioEssays. 2004;26: 1–5. doi: 10.1002/bies.10407 [DOI] [PubMed] [Google Scholar]
  • 6.Gettins P, Patston PA, Schapira M. The role of conformational change in serpin structure and function. Bioessays. 1993;15: 461–7. doi: 10.1002/bies.950150705 [DOI] [PubMed] [Google Scholar]
  • 7.Björk I, Olson ST. Antithrombin. A bloody important serpin. Advances in experimental medicine and biology. 1997. pp. 17–33. doi: 10.1007/978-1-4615-5391-5_3 [DOI] [PubMed] [Google Scholar]
  • 8.Corral J, de la Morena-Barrio ME, Vicente V. The genetics of antithrombin. Thromb Res. 2018;169: 23–29. doi: 10.1016/j.thromres.2018.07.008 [DOI] [PubMed] [Google Scholar]
  • 9.Hernández-Espinosa D, Ordóñez A, Vicente V, Corral J. Factors with conformational effects on haemostatic serpins: Implications in thrombosis. Thromb Haemost. 2007;98: 557–563. doi: 10.1160/TH07-02-0152 [DOI] [PubMed] [Google Scholar]
  • 10.Anfinsen CB. Principles that Govern the Folding of Protein Chains. Science (1979). 1973;181: 223–230. doi: 10.1126/science.181.4096.223 [DOI] [PubMed] [Google Scholar]
  • 11.Audagnotto M, Czechtizky W, De Maria L, Käck H, Papoian G, Tornberg L, et al. Machine learning/molecular dynamic protein structure prediction approach to investigate the protein conformational ensemble. Sci Rep. 2022;12: 10018. doi: 10.1038/s41598-022-13714-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021. doi: 10.1038/s41586-021-03819-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Callaway E. ‘It will change everything’: DeepMind’s AI makes gigantic leap in solving protein structures. Nature. 2020;588: 203–204. doi: 10.1038/d41586-020-03348-4 [DOI] [PubMed] [Google Scholar]
  • 14.Kryshtafovych A, Schwede T, Topf M, Fidelis K, Moult J. Critical assessment of methods of protein structure prediction (CASP)—Round XIII. Proteins: Structure, Function, and Bioinformatics. 2019;87: 1011–1020. doi: 10.1002/prot.25823 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, et al. Improved protein structure prediction using potentials from deep learning. Nature. 2020;577: 706–710. doi: 10.1038/s41586-019-1923-7 [DOI] [PubMed] [Google Scholar]
  • 16.Moult J, Fidelis K, Kryshtafovych A, Schwede T, Topf M. Critical Assessment of Techniques for Protein Structure Prediction, Fourteenth round. Abstract Book. 2020. [Google Scholar]
  • 17.Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, Žídek A, et al. Highly accurate protein structure prediction for the human proteome. Nature. 2021;596: 590–596. doi: 10.1038/s41586-021-03828-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.AplhaFold Protein Structure Database. 2021. [cited 20 Nov 2021]. Available: https://alphafold.ebi.ac.uk/faq [Google Scholar]
  • 19.Buel GR, Walters KJ. Can AlphaFold2 predict the impact of missense mutations on structure? Nat Struct Mol Biol. 2022;29: 1–2. doi: 10.1038/s41594-021-00714-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Pak MA, Markhieva KA, Novikova MS, Petrov DS, Vorobyev IS, Maksimova ES, et al. Using AlphaFold to predict the impact of single mutations on protein stability and function. PLoS One. 2023;18. doi: 10.1371/journal.pone.0282689 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Klepeis JL, Lindorff-Larsen K, Dror RO, Shaw DE. Long-timescale molecular dynamics simulations of protein structure and function. Curr Opin Struct Biol. 2009;19: 120–127. doi: 10.1016/j.sbi.2009.03.004 [DOI] [PubMed] [Google Scholar]
  • 22.McCammon JA, Gelin BR, Karplus M. Dynamics of folded proteins. Nature. 1977;267: 585–590. doi: 10.1038/267585a0 [DOI] [PubMed] [Google Scholar]
  • 23.Casalino L, Gaieb Z, Goldsmith JA, Hjorth CK, Dommer AC, Harbison AM, et al. Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. ACS Cent Sci. 2020;6: 1722–1734. doi: 10.1021/acscentsci.0c01056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Herrera-Nieto P, Pérez A, De Fabritiis G. Characterization of partially ordered states in the intrinsically disordered N-terminal domain of p53 using millisecond molecular dynamics simulations. Sci Rep. 2020;10: 12402. doi: 10.1038/s41598-020-69322-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Zimmerman MI, Porter JR, Ward MD, Singh S, Vithani N, Meller A, et al. SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome. Nat Chem. 2021;13: 651–659. doi: 10.1038/s41557-021-00707-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.de la Morena-Barrio M, Sandoval E, Llamas P, Wypasek E, Toderici M, Navarro-Fernández J, et al. High levels of latent antithrombin in plasma from patients with antithrombin deficiency. Thromb Haemost. 2017;117: 880–888. doi: 10.1160/TH16-11-0866 [DOI] [PubMed] [Google Scholar]
  • 27.Orlando C, de la Morena-Barrio B, Pareyn I, Vanhoorelbeke K, Martínez-Martínez I, Vicente V, et al. Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency. Thromb Haemost. 2021;121: 182–191. doi: 10.1055/s-0040-1716531 [DOI] [PubMed] [Google Scholar]
  • 28.Corral J, Rivera J, Martinez C, Gonzalez-Conejero R, Minano A, Vicente V. Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. Journal of Laboratory and Clinical Medicine. 2003;142: 298–305. doi: 10.1016/S0022-2143(03)00136-7 [DOI] [PubMed] [Google Scholar]
  • 29.Mushunje A, Evans G, Brennan SO, Carrell RW, Zhou A. Latent antithrombin and its detection, formation and turnover in the circulation. Journal of Thrombosis and Haemostasis. 2004;2: 2170–2177. doi: 10.1111/j.1538-7836.2004.01047.x [DOI] [PubMed] [Google Scholar]
  • 30.Martínez-Martínez I, Ordóñez A, Navarro-Fernández J, Pérez-Lara Á, Gutiérrez-Gallego R, Giraldo R, et al. Antithrombin Murcia (K241E) causing antithrombin deficiency: A possible role for altered glycosylation. Haematologica. 2010;95: 1358–1365. doi: 10.3324/haematol.2009.015487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proceedings of the National Academy of Sciences. 1984;81: 289–293. doi: 10.1073/pnas.81.2.289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Corral J, Huntington JA, González-Conejero R, Mushunje A, Navarro M, Marco P, et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. Journal of Thrombosis and Haemostasis. 2004;2: 931–939. doi: 10.1111/j.1538-7836.2004.00749.x [DOI] [PubMed] [Google Scholar]
  • 33.Jochmans K, Lissens W, Yin T, Michiels J, van der Luit L, Peerlinck K, et al. Molecular basis for type 1 antithrombin deficiency: identification of two novel point mutations and evidence for a de novo splice site mutation. Blood. 1994;84: 3742–3748. doi: 10.1182/blood.V84.11.3742.bloodjournal84113742 [DOI] [PubMed] [Google Scholar]
  • 34.Martínez-Martínez I, Johnson DJD, Yamasaki M, Navarro-Fernández J, Ordóñez A, Vivente V, et al. Type II antithrombin deficiency caused by a large in-frame insertion: structural, functional and pathological relevance. Journal of Thrombosis and Haemostasis. 2012;10: 1859–1866. doi: 10.1111/j.1538-7836.2012.04839.x [DOI] [PubMed] [Google Scholar]
  • 35.Protein Preparation Wizard—Schrödinger LLC. Schrödinger Release 2020–4: Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2020; Impact, Schrödinger, LLC, New York, NY; Prime, Schrödinger, LLC, New York, NY, 2020. 2020. [Google Scholar]
  • 36.DeepMind. AlphaFold.ipynb. 2021. [Google Scholar]
  • 37.Evans R, O’Neill M, Pritzel A, Antropova N, Senior A, Green T, et al. Protein complex prediction with AlphaFold-Multimer. bioRxiv. 2022. doi: 10.1101/2021.10.04.463034 [DOI] [Google Scholar]
  • 38.Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Science. 2021;30: 70–82. doi: 10.1002/pro.3943 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Mills JEJ, Dean PM. Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. J Comput Aided Mol Des. 1996. doi: 10.1007/BF00134183 [DOI] [PubMed] [Google Scholar]
  • 40.Moretti R, Lyskov S, Das R, Meiler J, Gray JJ. Web-accessible molecular modeling with Rosetta: The Rosetta Online Server that Includes Everyone (ROSIE). Protein Science. 2018;27: 259–268. doi: 10.1002/pro.3313 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Nosé S. A molecular dynamics method for simulations in the canonical ensemble. Mol Phys. 1984;52: 255–268. doi: 10.1080/00268978400101201 [DOI] [Google Scholar]
  • 42.Desmond—Schrödinger LCC. Schrödinger Release 2020–4: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2020. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY; 2020. [Google Scholar]
  • 43.Maestro version 9.4 Schrödinger LCC. Schrödinger Release 2020–4: Maestro. Schrödinger LCC, New York, NY; 2020. [Google Scholar]
  • 44.Hoover WG. Canonical dynamics: Equilibrium phase-space distributions. Phys Rev A (Coll Park). 1985;31: 1695–1697. doi: 10.1103/physreva.31.1695 [DOI] [PubMed] [Google Scholar]
  • 45.Martyna GJ, Tobias DJ, Klein ML. Constant pressure molecular dynamics algorithms. J Chem Phys. 1994;101: 4177–4189. doi: 10.1063/1.467468 [DOI] [Google Scholar]
  • 46.Roos K, Wu C, Damm W, Reboul M, Stevenson JM, Lu C, et al. OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules. J Chem Theory Comput. 2019;15: 1863–1874. doi: 10.1021/acs.jctc.8b01026 [DOI] [PubMed] [Google Scholar]
  • 47.Mariani V, Biasini M, Barbato A, Schwede T. lDDT: a local superposition-free score for comparing protein structures and models using distance difference tests. Bioinformatics. 2013;29: 2722–2728. doi: 10.1093/bioinformatics/btt473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2: 19–25. doi: 10.1016/j.softx.2015.06.001 [DOI] [Google Scholar]
  • 49.Hunter JD. Matplotlib: A 2D Graphics Environment. Comput Sci Eng. 2007;9: 90–95. doi: 10.1109/MCSE.2007.55 [DOI] [Google Scholar]
  • 50.Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: the human genomic variant search engine. Wren J, editor. Bioinformatics. 2019;35: 1978–1980. doi: 10.1093/bioinformatics/bty897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.BioLuminate—Schrödinger LLC. Schrödinger Release 2020–4: BioLuminate, New York, NY. 2020.
  • 52.Arocas V, Bock SC, Olson ST, Björk I. The role of Arg46 and Arg47 of antithrombin in heparin binding. Biochemistry. 1999;38: 10196–10204. doi: 10.1021/bi990686b [DOI] [PubMed] [Google Scholar]
  • 53.Olson S, Chuang Y-J. Heparin Activates Antithrombin Anticoagulant Function by Generating New Interaction Sites (Exosites) for Blood Clotting Proteinases. Trends Cardiovasc Med. 2002;12: 331–338. doi: 10.1016/s1050-1738(02)00183-4 [DOI] [PubMed] [Google Scholar]
  • 54.de la Morena-Barrio ME, López-Gálvez R, Martínez-Martínez I, Asenjo S, Sevivas TS, López MF, et al. Defects of splicing in antithrombin deficiency. Res Pract Thromb Haemost. 2017;1: 216–222. doi: 10.1002/rth2.12025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Gyebi GA, Ogunyemi OM, Adefolalu AA, Rodríguez-Martínez A, López-Pastor JF, Banegas-Luna AJ, et al. African derived phytocompounds may interfere with SARS-CoV-2 RNA capping machinery via inhibition of 2′-O-ribose methyltransferase: An in silico perspective. J Mol Struct. 2022;1262: 133019. doi: 10.1016/j.molstruc.2022.133019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Hernández-Espinosa D, Mota R, Miñano A, Ordóñez A, Yélamos J, Vicente V, et al. In vivo effects of hyperthermia on the functional and conformational characteristics of antithrombin. Journal of Thrombosis and Haemostasis. 2007;5: 963–970. doi: 10.1111/j.1538-7836.2007.02479.x [DOI] [PubMed] [Google Scholar]
  • 57.Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta Mol Basis Dis. 2001;1535: 221–235. doi: 10.1016/s0925-4439(01)00025-4 [DOI] [PubMed] [Google Scholar]
  • 58.Carrell RW, Read RJ. How serpins transport hormones and regulate their release. Semin Cell Dev Biol. 2017;62: 133–141. doi: 10.1016/j.semcdb.2016.12.007 [DOI] [PubMed] [Google Scholar]
  • 59.Pearce MC, Powers GA, Feil SC, Hansen G, Parker MW, Bottomley SP. Identification and Characterization of a Misfolded Monomeric Serpin Formed at Physiological Temperature. J Mol Biol. 2010;403: 459–467. doi: 10.1016/j.jmb.2010.09.007 [DOI] [PubMed] [Google Scholar]
  • 60.Arolas JL, Ventura S. Protease inhibitors as models for the study of oxidative folding. Antioxid Redox Signal. 2011;14: 97–112. doi: 10.1089/ars.2010.3456 [DOI] [PubMed] [Google Scholar]
  • 61.Dimova EY, Samoylenko A, Kietzmann T. Oxidative Stress and Hypoxia: Implications for Plasminogen Activator Inhibitor-1 Expression. Antioxid Redox Signal. 2004;6: 777–791. doi: 10.1089/1523086041361596 [DOI] [PubMed] [Google Scholar]
  • 62.Carrell RW, Huntington JA, Mushunje A, Zhou A. The conformational basis of thrombosis. Thromb Haemost. 2001;86: 14–22. doi: 10.1055/s-0037-1616196 [DOI] [PubMed] [Google Scholar]
  • 63.Corral J, Vicente V, Carrell RW. Thrombosis as a conformational disease. Haematologica. 2005;90: 238–46. [PubMed] [Google Scholar]
  • 64.Martínez-Martínez I, Navarro-Fernández J, Aguila S, Miñano A, Bohdan N, De La Morena-Barrio ME, et al. The infective polymerization of conformationally unstable antithrombin mutants may play a role in the clinical severity of antithrombin deficiency. Mol Med. 2012;18: 762–770. doi: 10.2119/molmed.2012.00017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Zhou A, Huntington JA, Carrell RW. Formation of the Antithrombin Heterodimer In Vivo and the Onset of Thrombosis. Blood. 1999;94: 3388–3396. doi: 10.1182/blood.V94.10.3388.422k20_3388_3396 [DOI] [PubMed] [Google Scholar]
  • 66.Schreuder H, de Boer B, Pronk S, Hol W, Dijkema R, Mulders J, et al. Crystallization and Preliminary X-ray Analysis of Human Antithrombin III. J Mol Biol. 1993;229: 249–250. doi: 10.1006/jmbi.1993.1024 [DOI] [PubMed] [Google Scholar]
  • 67.Wardell MR, Abrahams J-P, Bruce D, Skinner R, Leslie AGW. Crystallization and Preliminary X-ray Diffraction Analysis of Two Conformations of Intact Human Antithrombin. J Mol Biol. 1993;234: 1253–1258. doi: 10.1006/jmbi.1993.1676 [DOI] [PubMed] [Google Scholar]
  • 68.Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3 å structure of dimeric antithrombin. Structure. 1994;2: 257–270. doi: 10.1016/S0969-2126(00)00028-9 [DOI] [PubMed] [Google Scholar]
  • 69.Shaw DE, Adams PJ, Azaria A, Bank JA, Batson B, Bell A, et al. Anton 3: twenty microseconds of molecular dynamics simulation before lunch. Proceedings of the International Conference for High Performance Computing, Networking, Storage and Analysis. New York, NY, USA: ACM; 2021. pp. 1–11. doi: 10.1145/3458817.3487397 [DOI] [Google Scholar]
  • 70.Do P-C, Lee EH, Le L. Steered Molecular Dynamics Simulation in Rational Drug Design. J Chem Inf Model. 2018;58: 1473–1482. doi: 10.1021/acs.jcim.8b00261 [DOI] [PubMed] [Google Scholar]
  • 71.Lee T-S, Cerutti DS, Mermelstein D, Lin C, LeGrand S, Giese TJ, et al. GPU-Accelerated Molecular Dynamics and Free Energy Methods in Amber18: Performance Enhancements and New Features. J Chem Inf Model. 2018;58: 2043–2050. doi: 10.1021/acs.jcim.8b00462 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Cavalli A, Spitaleri A, Saladino G, Gervasio FL. Investigating Drug–Target Association and Dissociation Mechanisms Using Metadynamics-Based Algorithms. Acc Chem Res. 2015;48: 277–285. doi: 10.1021/ar500356n [DOI] [PubMed] [Google Scholar]
  • 73.Liu J, Zhao K-L, He G-X, Wang L-J, Zhou X-G, Zhang G-J. A de novo protein structure prediction by iterative partition sampling, topology adjustment and residue-level distance deviation optimization. Gorodkin J, editor. Bioinformatics. 2021;38: 99–107. doi: 10.1093/bioinformatics/btab620 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Soumendranath Bhakat

23 Oct 2023

PONE-D-23-28110Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpinsPLOS ONE

Dear Dr. Corral,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Thank you for submitting your manuscript titled "Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins" to PlosOne. We appreciate the time and effort you have put into this research.

While the core idea presented in your manuscript is intriguing and holds promise, there are several areas, as noted by our esteemed reviewers, that need further refinement and attention. I highly suggest to address the major revisions highlighted by reviewer 1 and looking forward to consider the revised version of the article in near future.

==============================

Please submit your revised manuscript by Dec 07 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Soumendranath Bhakat

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

4. We note that Figure 1, 2, 3, 4, 5 and 6 in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure 1, 2, 3, 4, 5 and 6 to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission. 

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

Additional Editor Comments:

Dear Authors,

Thank you for submitting your manuscript titled "Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins" to PlosOne. We appreciate the time and effort you have put into this research.

Following a rigorous review process, it has been determined that your submission requires a 'Major Revision'. While the core idea presented in your manuscript is intriguing and holds promise, there are several areas, as noted by our esteemed reviewers, that need further refinement and attention.

We believe that with these revisions, your work can be of significant value to our readership. I am genuinely looking forward to reviewing a more polished version of your article in the near future.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: While the manuscript presents a clear and interesting story for a broad audience, further details, analysis, and clarification is needed across many sections. See attached document for complete comments.

Reviewer #2: In this manuscript, authors have used Alphafold, Rosetta and short molecular dynamics simulations to predict structural properties of 5 mutants/variants of serpins. As it is already known in the field, the authors find that these tools are not powerful enough to predict the effects of mutations on the protein structure. Thus, this study does not provide any new insights. Besides, the authors have not provided sufficient details on the methods and analysis presented in this manuscript. Therefore, I cannot recommend this manuscript for publication. Please find my specific comments below:

1. Authors describe various conformational states of serpins using the terms “native”, “stressed”, “hyperstable”, and “relaxed structure”. However, these terms are not properly defined in the introduction and there is an ambiguity in the usage of these terms in the manuscript. This makes it difficult to understand which structural state is being discussed. Authors must define these terms and be consistent in the usage of these terms throughout the manuscript. Besides, figures showing these structural states is required for the purpose of clarity.

2. In the methods section, it is mentioned that the data was collected from 350 patients, and 135 unique genetic variations were found among 250 samples. What about remaining 100 patients? Further, the authors mention that anti-FXa and anti-FIIa activities measured. Authors must explain anti-FXa and anti-FIIa activities.

3. What was the reference structure used for computing RMSD values given in Table 2?

4. In Table 3, what is the meaning of “RMSD pruned”? What do Structure A and Structure B imply in the context of RMSD values presented in the table?

5. Ultimately, authors conclude that Alphafold and/or short MD simulations alone are not apt for predicting structural effects of mutations which is already known in the field. While the authors acknowledge that large-scale simulations could potentially predict the structural effects of mutations, they haven’t cited a recent study (https://doi.org/10.48550/arXiv.2309.03649) which demonstrates that Alphafold combined with enhanced sampling MD simulations could potentially predict the effect of mutations on the structure and dynamics of a protein.

Further, the authors mention that the structural predictions by Alphafold are heavily biased by the available structures of Serpin in PDB database. However, they do not discuss the studies demonstrating that this limitation can be circumvented by variations in the input parameters provided for the multiple sequence alignment of Alphafold prediction and combining the structural predictions with the enhanced sampling methods (https://doi.org/10.1016/j.sbi.2023.102645, https://doi.org/10.1021/acs.jctc.2c01189 ).

Overall, this study does not provide any new understanding and overlooks existing studies on structural predictions by AlphaFold combined with MD simulations.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Neha Vithani

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: 2023-Oct-12-PLOSOne-Serpins-Review.docx

pone.0304451.s008.docx (22.8KB, docx)
Attachment

Submitted filename: review.pdf

pone.0304451.s009.pdf (20.4KB, pdf)
PLoS One. 2024 Jul 5;19(7):e0304451. doi: 10.1371/journal.pone.0304451.r002

Author response to Decision Letter 0


23 Feb 2024

Dear Dr. Chenette,

Thank you for allowing us to answer the questions arising from our draft manuscript entitled “Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins”, submitted to PLOS ONE. We appreciate the time and effort that you and the reviewers have invested in providing us with your feedback. We have discussed all your comments and included changes to reflect the most of your suggestions. We have highlighted the changes in the manuscript.

Additionally, here is a point-by-point response to the reviewers’ comments and concerns.

Journal comments

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Thank you for your feedback. We have modified the manuscript format to adapt the document to the requirements. We would like you to confirm whether these changes meet the Journal requirements in the new manuscript version.

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

We apologize for this mistake. We have tried to modify the "Financial Disclosure" on the submission system. Unfortunately, we were not able to do so. We kindly ask the Editors to consider as correct the stated on the Financial Disclosure in the revised manuscript, and on the Funding Information section of the submission portal.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

We could not find the mentioned ethics statement outside the Methods section in our manuscripts. We would like to kindly ask the Journal if the novel manuscript version is suitable regarding this point.

4. We note that Figure 1, 2, 3, 4, 5 and 6 in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright. We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure 1, 2, 3, 4, 5 and 6 to publish the content specifically under the CC BY 4.0 license. We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text: “I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.” Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission. In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

We find this point may arise from the preprint version of the unreviewed manuscript, available on DOI: https://doi.org/10.1101/2023.01.31.526415. This preprint is authored by us, and we are the copyright owners of these figures. Given the preprint nature of such document, we would like to check if the preprint policy of the Journal is still the detailed in https://journals.plos.org/plosone/s/submission-guidelines#loc-manuscripts-disputing-published-work - Preprints. Nonetheless, following Reviewer 1 advice, we have opted for a major figure redesign, as detailed below herein, in the manuscript and in the submitted figure files. Thus, the figures detailed in this point are no longer present in the manuscript.

Reviewer 1

Review of “Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins”

This work seeks to probe whether or not AlphaFold2 (AF2), a structure prediction AI tool, is capable of probing the impact of clinically occurring disease-associated mutations in serpins (serine protease inhibitors). The authors present a biophysical model in which disease-associated mutations cause a conformational change in a model serpin, SERPINC1, and test AF2’s ability to predict these changes. Their results demonstrate a key finding that is relevant to a broad audience: that AF2 remains unable to wholly predict global conformational shifts and changes upon mutation/insertion of residues. I laude the authors’ clarity in presenting a clear-cut story using a biologically interesting model system that has clinical relevance, and their creative use of drawing upon patient data to select mutations. Not only have the authors presented a clear problem and question, they use as many open-source tools as possible to tackle their hypothesis, and even shared their data demonstrating a commitment to Open Science. However, at the current stage the manuscript remains largely devoid of necessary details that must be included prior to publication (as described in major revisions). Furthermore, the figures require significant editing to ensure that a reader can understand the data provided. Lastly, while the authors present a very useful biophysical model to probe the power of AF2, they only provide structural details regarding a single state - it will be critical to include structural depictions of both models to allow the reader to compare and contrast any structural predictions.

We thank again Reviewer 1 for their suggestions to improve our manuscript. We have updated such sections in the revised manuscript to try and address the ideas the Reviewer presents on this point.

Major Revisions

1. The authors do not provide any sort of experimental data in the SI or main text about their immunoelectrophoretic experiments, western blots, PAGE results, and beyond, and should provide the data in the manuscript itself, or provide clear citations to find the relevant data. While the use of this method to study the oligomerization and functional behaviors of their clinical mutants is reasonable, the only data provided is a single table with unitless values, and it remains unclear whether these values were obtained using densitometry or other approaches. I would ask that the authors at least include critically relevant blots that convey the functional impact of their top 5 mutants in the manuscript (or supporting information).

We apologize for the unclear way to show the methods used in our manuscript. The main objective of this study was to test the accuracy of AlphaFold following MD predictions for mutations with conformational consequences in antithrombin, an anticoagulant serpin. Thus, we considered that a large description of all biochemical methods used to characterize the aberrant forms of antithrombin identified in patients with the selected SERPINC1 mutations was out of the scope of this manuscript. Moreover, all these methods have been described by our group elsewhere, and all references to these methods are already included in the manuscript and further clarified. Additionally, figures with blots, proteomic or crystallographic data that convey the functional impact of their top 5 mutants in the manuscript generated with carriers of these mutations by our group have been published previously. All these references are included in the manuscript and available for verification.

2. I request that the authors greatly expand the methods section, both for their experimental work as well as for their computational studies. At present, the details provided on their immunoelectrophoretic methods, separation and unfolding experiments, and semi-quantitative determination are lacking critical details that prevent any reader from trying to replicate their work. These omissions must be fixed prior to publication.

Again, we apologize for not clearly presenting the references in which experimental data for all variants can be accessed both by reviewers and readers. Following this and the previous points, we have included the references describing these variants in Table 1. We have also included further details on the description of computational methods, adding descriptions and new references for additional details on this matter.

Regarding AlphaFold, we have included additional details: dimerization models were obtained with AlphaFold Multimer. UCSF ChimeraX was used to obtain metrics and figures for AlphaFold results. Pruned RMSD refers to RMSD computed excluding from the process unstructured or flexible structures to avoid potential biases on the RMSD computations. These results were presented using PyMol. Hydrogen bond analysis was performed with ChimeraX as described elsewhere.

For MD, we create a new section of Materials and Methods, to specify how the original structures were preprocessed to run MD. This section is called "Structure processing". Also, we included in the MD methods the tool used to create the water box (System Builder of Maestro Suite).

3. While their computational model descriptions are sufficiently detailed for replication, it would be useful if the authors were to expand on the structures, they used to start these simulations, a key missing detail. Additionally, the authors should report the implementation of lDDT and RMSD that was used.

We appreciate the referee’s suggestion of the expansion of the explanation about the method to obtain the structures to run the MD. The crystal structures of Wild Type (1AZX-I) and M5(4EB1-I), and the AlphaFold predictions were used to run the MD. As we said in the revised manuscript, all the structures were preprocessed using the Maestro Tool Protein Preparation Wizard to avoid all problems with hydrogens that could crash between them. The proteins were processed to add the charges using the Maestro tool System Builder.

lDDT:

Regarding the local Distance Difference Test (lDDT) was performed using the lDDT tool of swiss-model (https://swissmodel.expasy.org/lddt/downloads/) , the lDDT score is a measurement of the difference between the local interactions of the two proteins. This tool was used in the CAPS9 (Critical Assessment of protein Structure Prediction 9: https://predictioncenter.org/casp9/index.cgi).

RMSD:

Regarding the Root Mean Square Deviation (RMSD) was calculated using the Maestro tool Simulation Interactions Diagram (SID). This tool takes the first frame as a reference and superimposes all the frames against the reference to evaluate the fluctuation of the protein along the trajectory. The values that are higher than 3 A indicate that the protein is not stable.

The manuscript has been updated to include these explanations.

4. While the conformational hypothesis the authors present is presented in a logical manner, I would ask that they provide further detail and expand in the introduction on why they think conformation has any basis on the impact of mutations, and that other mechanistic details are not relevant. This detail is needed to demonstrate that the conformational impact of mutations in SERPINC1 are sufficient to predict disease relevance. For instance, if mutations in SERPINC1 instead primarily cause an inability to bind to heparin, resulting in the clinical phenotype, by changing the heparin binding site without any significant conformational changes, prediction of conformational change from the WT state is insufficient to predict clinical relevance. Alternatively, if the primary change is in the likelihood of oligomerization, perhaps a tool like AlphaFold Multimer would be more appropriate (bioRxiv 2021.10.04.463034). The authors current dive into their conformational model would be vastly supported by additional explanation as to why conformation dynamics may play a role here.

We acknowledge the correct and appropriate comment of Reviewer 1. The serpin superfamily has a pretty conserved structure needed for them to function, as their native (stressed) conformation allow them to run a suicidal inhibitory mechanism. These mutations disrupt the native (functional) structure, leading either to latent (relaxed) or dimers / polymers, losing the ability to inhibit via the mentioned suicidal mechanism. In the revised manuscript we have expanded the Introduction to support the functional or conformational consequences of mutations in antithrombin and their clinical effects.

Additionally, we have run AlphaFold Multimer to test variants causing dimerization of antithrombin. We found both M2 and M4 do form dimers. Nonetheless, we also find AlphaFold Multimer output dimers for wild-type. Indeed, the dimer structure AlphaFold computes form M2 and M4 is the same as the computed for the wild-type sequence, exchanging one β-strand with the A sheet of the other molecule. Moreover, the dimer computed does not correspond to the experimentally determined models (such as PDB: 2ZNH, Fig 1D of revised manuscript), in which two β-strands are exchanged between the two counterparts. We include images presenting each scenario (S2 Fig. of revised manuscript) for further clarification on our results regarding AlphaFold Multimer, highlighting in purple the β-strands exchanged.

5. Importantly, I would ask that the authors provide *both* structural models of their two conformations (“stressed”, represented by 1AZX in the PDB, and “relaxed”, represented by 4EB1) in their figures and explicitly clarify that the “p.Glu241…” variant was crystalized by the same lab (PDB: 4EB1). At present, it seems like the authors are only presenting figures of the “stressed” conformation and not providing any further figures/structural details on the disease-associated relaxed state, despite it being more predictive of disease-association. It would be important to provide the reader with structural details of both states, and to overlay them alongside the AF2 predictions, to allow for visual comparison. In particular, after examining the 4EB1 and 1AZX structures, it is not immediately obvious what the consequences of the additional strand in the beta-sheet are. Most of the structure is the same, with an RMSD between the chain “I” of both structures ~1.268 Å according to PyMol. I can imagine that there could be significant changes, but making them clearer in the paper is essential.

Again, we would like to thank Reviewer 1 on their comments, as we think their suggestions allowed us to greatly improve our manuscript. Following their advice, we’ve stated tha

Attachment

Submitted filename: Response letter R1.pdf

pone.0304451.s010.pdf (426.5KB, pdf)

Decision Letter 1

Soumendranath Bhakat

26 Mar 2024

PONE-D-23-28110R1Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpinsPLOS ONE

Dear Dr. Corral,

Thank you for submitting your manuscript to PLOS ONE. I appreciate your patience. We have now completed the reviewing process by an independent reviewer and I am happy to accept the revised manuscript after you address the comments of the reviewer and update the manuscript accordingly. Thanks for understanding and looking forward to receive the updated manuscript.

Best regards,

Soumendranath Bhakat

Please submit your revised manuscript by May 10 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Soumendranath Bhakat

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: The author of the manuscript has applied some recent tools like AF and Rosetta to predict the structure of wild-type and mutant SERPINS, after addressing some of the reviewer’s comments the manuscript quality has improved. However, still, this manuscript lacks some basic fundamental questions.

1. The authors have used no template and BDF for the structure prediction via AF. But what happens when we use wild type as a template to predict the mutant state? Does it yield a better structure prediction?

2. As we know the basics of any structure prediction is comparing the dihedrals (chi, phi, psi, and omega) of mutant residue predicted with PDB structure. Computing RMSD and RMSFs does not zoom into the effect of mutations. This can be easily done for M5.

3. Is there experimental evidence that validates the REU analysis in Table 4 that all mutations have a destabilizing effect?

4. In Table 2 RMSD was done for which atoms?

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Jul 5;19(7):e0304451. doi: 10.1371/journal.pone.0304451.r004

Author response to Decision Letter 1


10 May 2024

R2: response letter

PONE-D-23-28110R1

Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins

Dear Dr. Chenette,

Thank you for allowing us to answer the questions arising from our draft manuscript, "Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins, " submitted to PLOS ONE. We appreciate the time and effort that you and the reviewers have invested in providing us with your feedback. We have discussed all your comments and included changes to reflect most of your suggestions. We have highlighted the changes in the manuscript. Here is a point-by-point response to the reviewers’ comments and concerns.

Reviewer 3

1. The authors have used no template and BDF for the structure prediction via AF. But what happens when we use wild type as a template to predict the mutant state? Does it yield a better structure prediction?

First, we thank Reviewer 3 for their comments on how to improve our manuscript.

AlphaFold relies on a custom database designed by DeepMind called Best Fantastic Database (BFD). AlphaFold developers allow users to choose between running the model relying on a full BFD (containing most sequences and structures logged in public databases) or a reduced version of the BFD. Thus, the capabilities of AlphaFold entirely rely on this BFD. In both cases, multiple proteins can affect the final result.

AlphaFold users cannot manually select a single input for the model to produce a result. Moreover, in that scenario, the output of AlphaFold may not be comparable to the results produced by both complete or reduced AlphaFold for the reason above.

Nonetheless, we have tested results comparing complete and reduced AlphaFold for wild-type and M5 sequences, finding no significant differences between the two results for any of the sequences tested. These results are presented in Table 2 of the manuscript.

2. As we know the basics of any structure prediction is comparing the dihedrals (chi, phi, psi, and omega) of mutant residue predicted with PDB structure. Computing RMSD and RMSFs does not zoom into the effect of mutations. This can be easily done for M5.

We are grateful to the reviewer for their suggestion. We calculated the dihedral angles of the residues near mutation (S204, E205, A206, I207, N208, T211, V212, L213, V214, and L215). When we compared the three previous residues after the mutation, we found differences between the crystal structure of the M5 and the prediction of AlphaFold. The crystal structure has β-sheets before the mutation, whilst the AlphaFold prediction introduces a right-handed α-helix. These results agree with those presented in Tables 5 and 6 and page 16 lines 319-323 (manuscript with tracking).

We also updated the manuscript with tables (S6 Table and S7 Table) containing information about dihedral angles.

3. Is there experimental evidence that validates the REU analysis in Table 4 that all mutations have a destabilizing effect?

This is an interesting point. As the mutations selected have been studied previously using experimental techniques, we have information on their behavior, mechanisms leading to disease, and other metrics.

For M1, the mechanism is on residue 79 itself. As Arg79 is a critical residue that directly interacts with heparin, the mutation to Cys (losing the positive charge associated with the Arg) severely impairs the interaction between antithrombin and heparin. The differential interaction between the WT molecule and the M1 variant with heparin was proved experimentally by crossed immunoelectrophoresis in the presence of heparin. Figure A shows the differential migration pattern of the molecules bound or not bound to heparin, both in the plasma of a healthy subject and in plasma of a heterozygous carrier of the p.Arg79Cys variant, as well as in recombinant WT and M1 variants. Thus, the pathological mechanism of this mutation is not structure-based, so we would not expect structure disruptions for this mutation.

Figure A. Electrophoretic assay of WT (Arg79) and M1 (Cys79) antithrombins by their interaction with heparin. Differences of plasma and recombinant antithrombins are shown.

The mechanism involved in antithrombin deficiency is different for mutations M2 and M3. M2 (p.Pro112Ser) leads to deficiency by creating abnormal antithrombin polymers that are mainly retained inside the cells. However, traces of disulphide-linked mutant dimers are detected in plasma, as our group has published elsewhere (J. Corral et al., “Mutations in the shutter region of antithrombin result in the formation of disulfide-linked dimers and severe venous thrombosis,” J. Thromb. Haemost., vol. 2, no. 6, pp. 931–939, 2004, doi: 10.1111/j.1538-7836.2004.00749.x). In this case, the mutation creates a structural disruption, and it is in line with the REU result for M2.

The last missense mutation, M3 (p.Met283Val), leads antithrombin to fold into a latent confirmation, with the RCL inserted as a new beta-strand in sheet A. The variant is secreted but has no anticoagulant activity and low affinity for heparin, as our group demonstrated previously (M. de la Morena-Barrio et al., “High levels of latent antithrombin in plasma from patients with antithrombin deficiency,” Thromb. Haemost., vol. 117, no. 5, pp. 880–888, 2017, doi: 10.1160/TH16-11-0866). There is a structural disruption in this case, but it is not as detected as in the M2 case with the REU metrics.

Thus, we find higher values of REU (more destabilization) for one of the mutations whose mechanism is based on structural disruptions (M2). Still, in contrast, we got lower REU values for M3 (structural disruption) than for M1 (whose mechanism does not change the protein structure). Overall, we find ROSIE 2 predictions may help to determine the pathogenicity potential of some mutations, but there seem to be better methods to evaluate missense mutations in serpins altogether.

We have included these observations in the new version of the manuscript to further clarify ROSIE 2's potential for assessing the pathogenicity of missense variants in serpins.

4. In Table 2 RMSD was done for which atoms?

Table 2 was computed using the heavy atoms of each structure pair, as provided by PyMol RMSD calculations.

We would like to thank Reviewer 3 again for their feedback. Their suggestions have improved the quality of the manuscript.

Attachment

Submitted filename: Response letter R2.pdf

pone.0304451.s011.pdf (123.3KB, pdf)

Decision Letter 2

Soumendranath Bhakat

14 May 2024

Analysis of AlphaFold and molecular dynamics structure predictions of mutations in serpins

PONE-D-23-28110R2

Dear Dr. Corral,

Dear Authors,

Thank you for submitting the revised version of PONE-D-23-28110 to PLOS ONE. I am pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Soumendranath Bhakat

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear Authors,

Thank you for submitting the revised version of PONE-D-23-28110 to PLOS ONE. After careful consideration, I am pleased to accept the latest version of your manuscript for publication.

Best regards,

Soumendranath Bhakat

Reviewers' comments:

Acceptance letter

Soumendranath Bhakat

25 Jun 2024

PONE-D-23-28110R2

PLOS ONE

Dear Dr. Corral,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Soumendranath Bhakat

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Ramachandran plots for structures analyzed.

    Mutant structures correspond to AlphaFold prediction for said variant. Plots entitled in caps and italics refer to stated PDB crystal structures.

    (TIF)

    pone.0304451.s001.tif (3.8MB, tif)
    S2 Fig. AlphaFold Multimer predictions.

    a) M2. b) M4. c) Wild-type. Green and blue: antithrombin. Purple: exchanged β-strand.

    (TIF)

    pone.0304451.s002.tif (3.6MB, tif)
    S3 Fig. Free Energy Landscape profiles for all studied proteins after analysis of their MD trajectories.

    The X and Y axes represent PC1 and PC2 PCA components and the Z axis free energy value. a) Wild-type, b) M1, c) M2, d) M3, e) M4, f) M5.

    (TIF)

    pone.0304451.s003.tif (1.5MB, tif)
    S1 File. Reports of MD simulations.

    WT, M3 and M5 were simulated at 300K, 313 K, and 373K. These reports contain information about RMSF, RMSD and SSE.

    (ZIP)

    pone.0304451.s004.zip (7.7MB, zip)
    S1 Table. Pathogenicity predictions for selected variants.

    (PDF)

    pone.0304451.s005.pdf (125.2KB, pdf)
    S2 Table. Comparing side-chain conformations of the wild-type and M5 mutant.

    An analysis of Chi1 and Chi2 dihedral angles from crystal structures and AlphaFold Predictions.

    (DOCX)

    pone.0304451.s006.docx (18.4KB, docx)
    S3 Table. Assessing the quality of the wild-type and M5 mutant structures.

    A comparison of G-factors from crystal structures and AlphaFold predictions.

    (DOCX)

    pone.0304451.s007.docx (18.8KB, docx)
    Attachment

    Submitted filename: 2023-Oct-12-PLOSOne-Serpins-Review.docx

    pone.0304451.s008.docx (22.8KB, docx)
    Attachment

    Submitted filename: review.pdf

    pone.0304451.s009.pdf (20.4KB, pdf)
    Attachment

    Submitted filename: Response letter R1.pdf

    pone.0304451.s010.pdf (426.5KB, pdf)
    Attachment

    Submitted filename: Response letter R2.pdf

    pone.0304451.s011.pdf (123.3KB, pdf)

    Data Availability Statement

    Code used to run AlphaFold is freely available on DeepMind’s GitHub (see references). Software used for MD is property of Schrödinger LCC. Thus, access to it might be restricted. GROMACS and matplotlib codes are available at https://manual.gromacs.org/current/download.html and https://matplotlib.org/stable/users/installing/index.html, respectively. Variants p.Arg79Cys, p.Pro112Ser, p.Met283Val, p.Pro352insValPheLeuPro and p.Glu241_Leu242delinsValLeuValLeuValAsnThrArgThrSer, mentioned in our work, are deposited in UniProt as VAR_007037, VAR_086227, VAR_027468, VAR_086198 and VAR_086197, respectively.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES